--- title: "TherapeuticsMD Inc. Company Profile" description: "Research and investment analysis framework for TherapeuticsMD Inc. SEC EDGAR lists its industry as Pharmaceutical Preparations." canonical: https://www.getswoopr.com/stocks/companies/therapeuticsmd-inc/ source: "Swoopr Investment: https://www.getswoopr.com" --- # TherapeuticsMD Inc. Company Profile ## Direct Answer **TherapeuticsMD Inc. (TXMD)** is a U.S.-listed company in Swoopr's Dow Jones U.S. Total Stock Market research set. SEC EDGAR lists its industry as **Pharmaceutical Preparations**. This profile is a research framework: it does not state company-specific segments, products, management, financial figures or historical claims that have not been verified against primary sources. The research objective is to determine how TherapeuticsMD Inc. converts pharmaceuticals, biotechnology, medical devices, diagnostics, care delivery or health-services infrastructure into durable per-share cash generation. The page therefore emphasizes revenue mechanics, customers, margins, capital intensity, cash conversion, competition, risks, scenario analysis and monitoring signals rather than a stock-price prediction. ## Company Snapshot | Field | Value | | --- | --- | | Company | TherapeuticsMD Inc. | | Primary ticker | TXMD | | Security lines mapped to issuer | TXMD | | SEC industry (SIC) | [Pharmaceutical Preparations](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=25743) | | Index | Dow Jones U.S. Total Stock Market Index | | Listing data as of | 2026-08-31 | | Content status | Research framework; company-specific facts not yet verified against primary sources | Unverified fields such as current CEO, headquarters, employee count, CIK, fiscal year end, reported segments and current financial figures are intentionally omitted from this profile. ## What the Company Does Investors studying TherapeuticsMD Inc. (TXMD) should treat the company as an operating system of customers, assets, costs, capital and competitive choices, not merely as a ticker. SEC EDGAR lists the industry of TherapeuticsMD Inc. as Pharmaceutical Preparations. Within that boundary, the analytical starting point is the sector's typical economic chain: pharmaceuticals, biotechnology, medical devices, diagnostics, care delivery or health-services infrastructure. A disciplined review therefore asks what changed operationally, how much capital was required, and whether the change can repeat. A strong review should test procedure or prescription volumes, clinical and regulatory milestones, and free cash flow together rather than treating any one figure as decisive. ## How the Company Makes Money Research on TherapeuticsMD Inc. (TXMD) is most productive when the business model, cash-flow engine and risk structure are separated from market sentiment. For TherapeuticsMD Inc., start by translating reported revenue into the operating causes behind it. In this sector those causes often include product adoption, procedure or prescription volumes, clinical and regulatory milestones, and reimbursement. The distinction is important because accounting results can move before, or after, the operating drivers that ultimately determine cash returns. The same discipline should be applied to return on invested capital, organic revenue growth, and gross margin, because a favorable top-line result can have very different implications depending on margin, capital intensity and cash conversion. ## Revenue Engine A useful way to analyze TherapeuticsMD Inc. (TXMD) is to begin with the operating mechanism rather than the share price. The customer map for TherapeuticsMD Inc. should be built from disclosed end markets rather than assumed from its sector label. Likely research categories to validate include hospitals, payers, pharmacies, and government health programs and research organizations. The analytical question is why those customers choose the offering, how concentrated the relationship is, and whether purchasing behavior is recurring or transactional. That framework helps separate durable improvement from temporary benefits created by pricing, mix, working capital or a favorable cycle. Evidence of switching costs, contractual duration, distribution reach or product criticality should be cited directly when present. - **Clinical And Regulatory Milestones**, For TherapeuticsMD Inc., verify whether this is material, record the latest disclosed direction, and connect it to revenue, margin, cash flow or balance-sheet strength. - **Reimbursement**, For TherapeuticsMD Inc., verify whether this is material, record the latest disclosed direction, and connect it to revenue, margin, cash flow or balance-sheet strength. - **New Indications**, For TherapeuticsMD Inc., verify whether this is material, record the latest disclosed direction, and connect it to revenue, margin, cash flow or balance-sheet strength. ## Business Segments and Reporting Map For TherapeuticsMD Inc. (TXMD), the central analytical task is to connect reported financial results to the underlying drivers that can persist across cycles. The most useful risk work on TherapeuticsMD Inc. links a risk to a measurable transmission mechanism. For this sector, relevant categories can include regulatory delay, patent or exclusivity loss, reimbursement pressure, and product safety. A risk matters through the revenue, margin, cash-flow or balance-sheet path it could affect, so it is not listed merely because it appears in a filing. That framework helps separate durable improvement from temporary benefits created by pricing, mix, working capital or a favorable cycle. Monitoring should therefore connect each risk to a leading indicator or disclosure that can be checked over time. ## Products, Services and Commercial Offerings The investment case for TherapeuticsMD Inc. (TXMD) becomes clearer when revenue drivers, cost behavior, balance-sheet demands and competitive constraints are examined together. Supply-chain analysis for TherapeuticsMD Inc. should identify where bargaining power sits from upstream inputs through end demand. A practical map begins with patients and care settings, moves through scientific research and intellectual property and clinical development or engineering, and ends with provider and payer channels. Company-specific suppliers or customers should only be named when supported by filings or other authoritative evidence. That framework helps separate durable improvement from temporary benefits created by pricing, mix, working capital or a favorable cycle. Concentration, lead times, geographic dependence and substitution difficulty are more informative than a decorative list of counterparties. ## Customers and Demand Structure A useful way to analyze TherapeuticsMD Inc. (TXMD) is to begin with the operating mechanism rather than the share price. Macro sensitivity should be tested rather than assumed. Variables worth checking for TherapeuticsMD Inc. include interest rates for development-stage issuers, demographics, health-care utilization, and government reimbursement policy. The goal is to determine whether these variables affect unit demand, pricing, financing cost, working capital, asset utilization or customer solvency. A disciplined review therefore asks what changed operationally, how much capital was required, and whether the change can repeat. A robust dossier distinguishes direct exposure from second-order correlations and avoids implying that every macro variable is equally important. - **Pharmacies**, For TherapeuticsMD Inc., verify whether this is material, record the latest disclosed direction, and connect it to revenue, margin, cash flow or balance-sheet strength. - **Government Health Programs And Research Organizations**, For TherapeuticsMD Inc., verify whether this is material, record the latest disclosed direction, and connect it to revenue, margin, cash flow or balance-sheet strength. - **Patients**, For TherapeuticsMD Inc., verify whether this is material, record the latest disclosed direction, and connect it to revenue, margin, cash flow or balance-sheet strength. ## Geographic Exposure A useful way to analyze TherapeuticsMD Inc. (TXMD) is to begin with the operating mechanism rather than the share price. Capital allocation is where operating performance is converted into per-share outcomes. For TherapeuticsMD Inc., follow where capital goes: internal investment, capital expenditures, acquisitions, divestitures, dividends, repurchases, debt changes and equity issuance. In a business like this, pipeline milestones and procedure or prescription volumes when relevant can be especially informative when interpreted alongside returns on incremental capital. The objective is not to forecast a stock price; it is to understand what evidence would strengthen or weaken the business case. The right question is not whether management spent more or less, but whether each use of capital improved durable cash-generation capacity per share. ## Business Model A useful way to analyze TherapeuticsMD Inc. (TXMD) is to begin with the operating mechanism rather than the share price. The financial statements of TherapeuticsMD Inc. should be read as one connected system. Income-statement growth means more when it is read against balance-sheet investment and cash-flow conversion: compare changes in procedure or prescription volumes when relevant with operating margin, free cash flow, and product concentration. Health-care economics are unusually dependent on evidence, regulation and reimbursement. Reported growth must be connected to product durability, exclusivity, clinical value, payer acceptance, manufacturing reliability and the cost of sustaining the next generation of products. That framework helps separate durable improvement from temporary benefits created by pricing, mix, working capital or a favorable cycle. Persistent divergence between earnings and cash generation deserves an explanation grounded in working capital, capital expenditures, non-cash compensation, acquisitions or other company-specific factors. For TherapeuticsMD Inc., verify the actual revenue mechanisms, recurring, transactional, subscription, licensing, advertising, spread, fee, product, manufacturing, service or another model, and document only the mechanisms supported by current filings. Health-care economics are unusually dependent on evidence, regulation and reimbursement. Reported growth must be connected to product durability, exclusivity, clinical value, payer acceptance, manufacturing reliability and the cost of sustaining the next generation of products. ## Company Economics Investors studying TherapeuticsMD Inc. (TXMD) should treat the company as an operating system of customers, assets, costs, capital and competitive choices, not merely as a ticker. SEC EDGAR lists the industry of TherapeuticsMD Inc. as Pharmaceutical Preparations. Within that boundary, the analytical starting point is the sector's typical economic chain: pharmaceuticals, biotechnology, medical devices, diagnostics, care delivery or health-services infrastructure. The objective is not to forecast a stock price; it is to understand what evidence would strengthen or weaken the business case. A strong review should test procedure or prescription volumes, clinical and regulatory milestones, and operating margin together rather than treating any one figure as decisive. ## How to Read the Income Statement A useful way to analyze TherapeuticsMD Inc. (TXMD) is to begin with the operating mechanism rather than the share price. For TherapeuticsMD Inc., start by translating reported revenue into the operating causes behind it. In this sector those causes often include capacity and commercial execution, product adoption, procedure or prescription volumes, and clinical and regulatory milestones. The distinction is important because accounting results can move before, or after, the operating drivers that ultimately determine cash returns. The same discipline should be applied to pipeline milestones, procedure or prescription volumes when relevant, and operating margin, because a favorable top-line result can have very different implications depending on margin, capital intensity and cash conversion. ## How to Read the Balance Sheet The investment case for TherapeuticsMD Inc. (TXMD) becomes clearer when revenue drivers, cost behavior, balance-sheet demands and competitive constraints are examined together. The customer map for TherapeuticsMD Inc. should be built from disclosed end markets rather than assumed from its sector label. Likely research categories to validate include payers, pharmacies, government health programs and research organizations, and patients. The analytical question is why those customers choose the offering, how concentrated the relationship is, and whether purchasing behavior is recurring or transactional. The objective is not to forecast a stock price; it is to understand what evidence would strengthen or weaken the business case. Evidence of switching costs, contractual duration, distribution reach or product criticality should be cited directly when present. ## How to Read Cash Flow For TherapeuticsMD Inc. (TXMD), the central analytical task is to connect reported financial results to the underlying drivers that can persist across cycles. The most useful risk work on TherapeuticsMD Inc. links a risk to a measurable transmission mechanism. For this sector, relevant categories can include litigation, manufacturing quality, clinical failure, and regulatory delay. A risk matters through the revenue, margin, cash-flow or balance-sheet path it could affect, so it is not listed merely because it appears in a filing. This matters because headline growth can look similar while the quality of that growth differs materially. Monitoring should therefore connect each risk to a leading indicator or disclosure that can be checked over time. ## Metrics That Matter Most Investors studying TherapeuticsMD Inc. (TXMD) should treat the company as an operating system of customers, assets, costs, capital and competitive choices, not merely as a ticker. Supply-chain analysis for TherapeuticsMD Inc. should identify where bargaining power sits from upstream inputs through end demand. A practical map begins with clinical development or engineering, moves through regulated manufacturing and provider and payer channels, and ends with scientific research and intellectual property. Company-specific suppliers or customers should only be named when supported by filings or other authoritative evidence. The distinction is important because accounting results can move before, or after, the operating drivers that ultimately determine cash returns. Concentration, lead times, geographic dependence and substitution difficulty are more informative than a decorative list of counterparties. - **Operating Margin**, For TherapeuticsMD Inc., verify whether this is material, record the latest disclosed direction, and connect it to revenue, margin, cash flow or balance-sheet strength. - **Free Cash Flow**, For TherapeuticsMD Inc., verify whether this is material, record the latest disclosed direction, and connect it to revenue, margin, cash flow or balance-sheet strength. - **Cash Runway For Pre-Profit Issuers**, For TherapeuticsMD Inc., verify whether this is material, record the latest disclosed direction, and connect it to revenue, margin, cash flow or balance-sheet strength. ## Competitive Position The investment case for TherapeuticsMD Inc. (TXMD) becomes clearer when revenue drivers, cost behavior, balance-sheet demands and competitive constraints are examined together. Macro sensitivity should be tested rather than assumed. Variables worth checking for TherapeuticsMD Inc. include demographics, health-care utilization, government reimbursement policy, and employment and insurance coverage. The goal is to determine whether these variables affect unit demand, pricing, financing cost, working capital, asset utilization or customer solvency. The objective is not to forecast a stock price; it is to understand what evidence would strengthen or weaken the business case. A robust dossier distinguishes direct exposure from second-order correlations and avoids implying that every macro variable is equally important. ## Industry Position Research on TherapeuticsMD Inc. (TXMD) is most productive when the business model, cash-flow engine and risk structure are separated from market sentiment. Capital allocation is where operating performance is converted into per-share outcomes. For TherapeuticsMD Inc., follow where capital goes: internal investment, capital expenditures, acquisitions, divestitures, dividends, repurchases, debt changes and equity issuance. In a business like this, pipeline milestones and procedure or prescription volumes when relevant can be especially informative when interpreted alongside returns on incremental capital. That framework helps separate durable improvement from temporary benefits created by pricing, mix, working capital or a favorable cycle. The right question is not whether management spent more or less, but whether each use of capital improved durable cash-generation capacity per share. ## Supply Chain and Dependencies A useful way to analyze TherapeuticsMD Inc. (TXMD) is to begin with the operating mechanism rather than the share price. The financial statements of TherapeuticsMD Inc. should be read as one connected system. Income-statement growth means more when it is read against balance-sheet investment and cash-flow conversion: compare changes in organic revenue growth with gross margin, research and development spending, and procedure or prescription volumes when relevant. Health-care economics are unusually dependent on evidence, regulation and reimbursement. Reported growth must be connected to product durability, exclusivity, clinical value, payer acceptance, manufacturing reliability and the cost of sustaining the next generation of products. A disciplined review therefore asks what changed operationally, how much capital was required, and whether the change can repeat. Persistent divergence between earnings and cash generation deserves an explanation grounded in working capital, capital expenditures, non-cash compensation, acquisitions or other company-specific factors. - **Patients And Care Settings**, For TherapeuticsMD Inc., verify whether this is material, record the latest disclosed direction, and connect it to revenue, margin, cash flow or balance-sheet strength. - **Scientific Research And Intellectual Property**, For TherapeuticsMD Inc., verify whether this is material, record the latest disclosed direction, and connect it to revenue, margin, cash flow or balance-sheet strength. - **Clinical Development Or Engineering**, For TherapeuticsMD Inc., verify whether this is material, record the latest disclosed direction, and connect it to revenue, margin, cash flow or balance-sheet strength. ## Economic Sensitivity Investors studying TherapeuticsMD Inc. (TXMD) should treat the company as an operating system of customers, assets, costs, capital and competitive choices, not merely as a ticker. SEC EDGAR lists the industry of TherapeuticsMD Inc. as Pharmaceutical Preparations. Within that boundary, the analytical starting point is the sector's typical economic chain: pharmaceuticals, biotechnology, medical devices, diagnostics, care delivery or health-services infrastructure. The objective is not to forecast a stock price; it is to understand what evidence would strengthen or weaken the business case. A strong review should test procedure or prescription volumes, clinical and regulatory milestones, and return on invested capital together rather than treating any one figure as decisive. - **Government Reimbursement Policy**, For TherapeuticsMD Inc., verify whether this is material, record the latest disclosed direction, and connect it to revenue, margin, cash flow or balance-sheet strength. - **Employment And Insurance Coverage**, For TherapeuticsMD Inc., verify whether this is material, record the latest disclosed direction, and connect it to revenue, margin, cash flow or balance-sheet strength. - **Interest Rates For Development-Stage Issuers**, For TherapeuticsMD Inc., verify whether this is material, record the latest disclosed direction, and connect it to revenue, margin, cash flow or balance-sheet strength. ## Capital Allocation A useful way to analyze TherapeuticsMD Inc. (TXMD) is to begin with the operating mechanism rather than the share price. The customer map for TherapeuticsMD Inc. should be built from disclosed end markets rather than assumed from its sector label. Likely research categories to validate include patients, providers, hospitals, and payers. The analytical question is why those customers choose the offering, how concentrated the relationship is, and whether purchasing behavior is recurring or transactional. The objective is not to forecast a stock price; it is to understand what evidence would strengthen or weaken the business case. Evidence of switching costs, contractual duration, distribution reach or product criticality should be cited directly when present. For TherapeuticsMD Inc., reconcile internal investment, acquisitions, divestitures, dividends, repurchases, debt changes and equity issuance. The useful question is whether each use of capital increases durable cash-generation capacity per share after considering risk and the opportunity cost of capital. ## Growth Drivers Research on TherapeuticsMD Inc. (TXMD) is most productive when the business model, cash-flow engine and risk structure are separated from market sentiment. The most useful risk work on TherapeuticsMD Inc. links a risk to a measurable transmission mechanism. For this sector, relevant categories can include clinical failure, regulatory delay, patent or exclusivity loss, and reimbursement pressure. A risk matters through the revenue, margin, cash-flow or balance-sheet path it could affect, so it is not listed merely because it appears in a filing. This matters because headline growth can look similar while the quality of that growth differs materially. Monitoring should therefore connect each risk to a leading indicator or disclosure that can be checked over time. - **Reimbursement**, For TherapeuticsMD Inc., verify whether this is material, record the latest disclosed direction, and connect it to revenue, margin, cash flow or balance-sheet strength. - **New Indications**, For TherapeuticsMD Inc., verify whether this is material, record the latest disclosed direction, and connect it to revenue, margin, cash flow or balance-sheet strength. - **Capacity And Commercial Execution**, For TherapeuticsMD Inc., verify whether this is material, record the latest disclosed direction, and connect it to revenue, margin, cash flow or balance-sheet strength. ## Risk Factors The investment case for TherapeuticsMD Inc. (TXMD) becomes clearer when revenue drivers, cost behavior, balance-sheet demands and competitive constraints are examined together. Supply-chain analysis for TherapeuticsMD Inc. should identify where bargaining power sits from upstream inputs through end demand. A practical map begins with scientific research and intellectual property, moves through clinical development or engineering and regulated manufacturing, and ends with patients and care settings. Company-specific suppliers or customers should only be named when supported by filings or other authoritative evidence. That framework helps separate durable improvement from temporary benefits created by pricing, mix, working capital or a favorable cycle. Concentration, lead times, geographic dependence and substitution difficulty are more informative than a decorative list of counterparties. - **Regulatory Delay**, For TherapeuticsMD Inc., verify whether this is material, record the latest disclosed direction, and connect it to revenue, margin, cash flow or balance-sheet strength. - **Patent Or Exclusivity Loss**, For TherapeuticsMD Inc., verify whether this is material, record the latest disclosed direction, and connect it to revenue, margin, cash flow or balance-sheet strength. - **Reimbursement Pressure**, For TherapeuticsMD Inc., verify whether this is material, record the latest disclosed direction, and connect it to revenue, margin, cash flow or balance-sheet strength. ## Bull, Base and Bear Operating Framework The investment case for TherapeuticsMD Inc. (TXMD) becomes clearer when revenue drivers, cost behavior, balance-sheet demands and competitive constraints are examined together. Macro sensitivity should be tested rather than assumed. Variables worth checking for TherapeuticsMD Inc. include employment and insurance coverage, interest rates for development-stage issuers, demographics, and health-care utilization. The goal is to determine whether these variables affect unit demand, pricing, financing cost, working capital, asset utilization or customer solvency. The distinction is important because accounting results can move before, or after, the operating drivers that ultimately determine cash returns. A robust dossier distinguishes direct exposure from second-order correlations and avoids implying that every macro variable is equally important. A bull case for TherapeuticsMD Inc. names the operating drivers that outperform, a base case describes normal execution, and a bear case identifies what deteriorates. Each case should use measurable business conditions rather than a target share price. ## What Could Prove an Investment Thesis Wrong? Research on TherapeuticsMD Inc. (TXMD) is most productive when the business model, cash-flow engine and risk structure are separated from market sentiment. Capital allocation is where operating performance is converted into per-share outcomes. For TherapeuticsMD Inc., follow where capital goes: internal investment, capital expenditures, acquisitions, divestitures, dividends, repurchases, debt changes and equity issuance. In a business like this, research and development spending and pipeline milestones can be especially informative when interpreted alongside returns on incremental capital. The distinction is important because accounting results can move before, or after, the operating drivers that ultimately determine cash returns. The right question is not whether management spent more or less, but whether each use of capital improved durable cash-generation capacity per share. ## What Investors Commonly Misunderstand For TherapeuticsMD Inc. (TXMD), the central analytical task is to connect reported financial results to the underlying drivers that can persist across cycles. The financial statements of TherapeuticsMD Inc. should be read as one connected system. Income-statement growth means more when it is read against balance-sheet investment and cash-flow conversion: compare changes in organic revenue growth with gross margin, research and development spending, and procedure or prescription volumes when relevant. Health-care economics are unusually dependent on evidence, regulation and reimbursement. Reported growth must be connected to product durability, exclusivity, clinical value, payer acceptance, manufacturing reliability and the cost of sustaining the next generation of products. That framework helps separate durable improvement from temporary benefits created by pricing, mix, working capital or a favorable cycle. Persistent divergence between earnings and cash generation deserves an explanation grounded in working capital, capital expenditures, non-cash compensation, acquisitions or other company-specific factors. Common analytical errors for TherapeuticsMD Inc. can include treating sector averages as company facts, confusing revenue growth with cash-value creation, ignoring share issuance or acquisition effects, and assuming a favorable cycle is permanent. Replace these general cautions with issuer-specific misconceptions after primary-source enrichment. ## What to Monitor A useful way to analyze TherapeuticsMD Inc. (TXMD) is to begin with the operating mechanism rather than the share price. SEC EDGAR lists the industry of TherapeuticsMD Inc. as Pharmaceutical Preparations. Within that boundary, the analytical starting point is the sector's typical economic chain: pharmaceuticals, biotechnology, medical devices, diagnostics, care delivery or health-services infrastructure. The objective is not to forecast a stock price; it is to understand what evidence would strengthen or weaken the business case. A strong review should test new indications, capacity and commercial execution, and organic revenue growth together rather than treating any one figure as decisive. - **Product Concentration**, For TherapeuticsMD Inc., verify whether this is material, record the latest disclosed direction, and connect it to revenue, margin, cash flow or balance-sheet strength. - **Return On Invested Capital**, For TherapeuticsMD Inc., verify whether this is material, record the latest disclosed direction, and connect it to revenue, margin, cash flow or balance-sheet strength. - **Organic Revenue Growth**, For TherapeuticsMD Inc., verify whether this is material, record the latest disclosed direction, and connect it to revenue, margin, cash flow or balance-sheet strength. ## Key Takeaways For TherapeuticsMD Inc. (TXMD), the central analytical task is to connect reported financial results to the underlying drivers that can persist across cycles. The customer map for TherapeuticsMD Inc. should be built from disclosed end markets rather than assumed from its sector label. Likely research categories to validate include patients, providers, hospitals, and payers. The analytical question is why those customers choose the offering, how concentrated the relationship is, and whether purchasing behavior is recurring or transactional. This matters because headline growth can look similar while the quality of that growth differs materially. Evidence of switching costs, contractual duration, distribution reach or product criticality should be cited directly when present. ## Questions Investors Should Ask For TherapeuticsMD Inc. (TXMD), the central analytical task is to connect reported financial results to the underlying drivers that can persist across cycles. For TherapeuticsMD Inc., start by translating reported revenue into the operating causes behind it. In this sector those causes often include new indications, capacity and commercial execution, product adoption, and procedure or prescription volumes. That framework helps separate durable improvement from temporary benefits created by pricing, mix, working capital or a favorable cycle. The same discipline should be applied to pipeline milestones, procedure or prescription volumes when relevant, and operating margin, because a favorable top-line result can have very different implications depending on margin, capital intensity and cash conversion. 1. What two or three variables explain most changes in TherapeuticsMD Inc.'s revenue? 2. Which costs at TherapeuticsMD Inc. are fixed, variable, or investment for future growth? 3. What evidence shows that TherapeuticsMD Inc. has, or lacks, pricing power? 4. Which customers or channels matter most, and is concentration changing? 5. How well do reported earnings at TherapeuticsMD Inc. convert to cash? 6. How much reinvestment is required to sustain the competitive position? 7. Which KPI would give the earliest warning of deterioration? 8. How exposed is TherapeuticsMD Inc. to health-care utilization and government reimbursement policy? 9. Is capital allocation improving per-share economics? 10. What evidence would invalidate a positive long-term thesis? ## FAQ Is TherapeuticsMD Inc. in the Dow Jones U.S. Total Stock Market Index? TherapeuticsMD Inc. (TXMD) is in the Dow Jones U.S. Total Stock Market Index company list Swoopr compiled from U.S. listing data as of 2026-08-31. S&P Dow Jones Indices publishes current official membership. What sector is TherapeuticsMD Inc. in? SEC EDGAR lists the industry of TherapeuticsMD Inc. as Pharmaceutical Preparations. That is an SEC filing classification, not a GICS sector. How does TherapeuticsMD Inc. make money? This profile does not yet describe an issuer-specific revenue model. The latest annual report on SEC EDGAR sets out revenue streams, pricing and reported segments; the framework on this page shows how to read them. What metrics matter for TherapeuticsMD Inc.? Candidate sector metrics include organic revenue growth, gross margin, research and development spending, pipeline milestones, procedure or prescription volumes when relevant. Keep only KPIs that current disclosures and the economics of TherapeuticsMD Inc. show are material. What are the principal risks for TherapeuticsMD Inc.? Start by testing clinical failure, regulatory delay, patent or exclusivity loss, reimbursement pressure, then add issuer-specific risks from current filings and connect each risk to an observable monitoring signal. Does this page recommend buying or selling TXMD? No. The dossier is educational research infrastructure and does not provide personalized investment advice or a price target. ## References - [S&P Dow Jones Indices: Dow Jones U.S. Total Stock Market Index](https://www.spglobal.com/spdji/en/indices/equity/dow-jones-us-total-stock-market-index/). Index identity and methodology context. - [S&P Dow Jones Indices methodology materials](https://www.spglobal.com/spdji/en/). Eligibility and maintenance framework. - [SEC EDGAR](https://www.sec.gov/edgar/search/). The SEC's company search is where to confirm TherapeuticsMD Inc.'s legal identity, filings, segments and risks, and to read its financial statements. ## More in This Section - [TherapeuticsMD Inc. Business Model Research Guide](https://www.getswoopr.com/stocks/companies/therapeuticsmd-inc/business-model/) - [TherapeuticsMD Inc. Metrics Guide](https://www.getswoopr.com/stocks/companies/therapeuticsmd-inc/financial-metrics/) - [TherapeuticsMD Inc. Risk Monitoring](https://www.getswoopr.com/stocks/companies/therapeuticsmd-inc/risks-monitoring/) **[Swoopr Editorial Team](https://www.getswoopr.com/authors/swoopr-editorial-team/)** Swoopr's editorial team produces independent investment education content reviewed for accuracy and clarity. We do not provide personalized financial advice. See our [editorial policy](https://www.getswoopr.com/legal/editorial-policy/) and [corrections policy](https://www.getswoopr.com/legal/corrections-policy/).